Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis
A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Sponsor: Amgen
Listed as NCT01785875, this PHASE3 trial focuses on Hyperparathyroidism, Secondary and remains completed. Sponsored by Amgen, it has been updated 9 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
May 2019 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Jun 2018 — May 2019 [monthly]
Completed PHASE3
-
May 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — May 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Jul 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalst, Belgium , Adelaide, Australia , Alexandria, United States , Amsterdam, Netherlands , Ancona, Italy , Arlington, United States , Arvada, United States , Ashkelon, Israel , Augusta, United States , Austin, United States and 167 more locations